CN1568369A - 杂合的干扰素/干扰素Tau蛋白、组合物和使用方法 - Google Patents

杂合的干扰素/干扰素Tau蛋白、组合物和使用方法 Download PDF

Info

Publication number
CN1568369A
CN1568369A CNA028199375A CN02819937A CN1568369A CN 1568369 A CN1568369 A CN 1568369A CN A028199375 A CNA028199375 A CN A028199375A CN 02819937 A CN02819937 A CN 02819937A CN 1568369 A CN1568369 A CN 1568369A
Authority
CN
China
Prior art keywords
interferon
protein
hybrid protein
hybrid
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA028199375A
Other languages
English (en)
Chinese (zh)
Inventor
L·H·维拉雷特
J·坎波斯
W·李
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pepgen Corp
Original Assignee
Pepgen Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pepgen Corp filed Critical Pepgen Corp
Publication of CN1568369A publication Critical patent/CN1568369A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
CNA028199375A 2001-08-12 2002-08-12 杂合的干扰素/干扰素Tau蛋白、组合物和使用方法 Pending CN1568369A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31186601P 2001-08-12 2001-08-12
US60/311,866 2001-08-12

Publications (1)

Publication Number Publication Date
CN1568369A true CN1568369A (zh) 2005-01-19

Family

ID=23208847

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA028199375A Pending CN1568369A (zh) 2001-08-12 2002-08-12 杂合的干扰素/干扰素Tau蛋白、组合物和使用方法

Country Status (7)

Country Link
US (1) US7232563B2 (https=)
EP (1) EP1425409A4 (https=)
JP (1) JP2005525784A (https=)
KR (1) KR20040022244A (https=)
CN (1) CN1568369A (https=)
CA (1) CA2454860A1 (https=)
WO (1) WO2003016472A2 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050118137A1 (en) * 2000-07-19 2005-06-02 Chih-Ping Liu Method of treatment using interferon-tau
US7083782B2 (en) * 2000-07-19 2006-08-01 Pepgen Corporation Method of treatment using interferon-tau
US7431920B2 (en) * 2000-07-19 2008-10-07 Pepgen Corporation Method of treating IL-10 deficiency
US20050201981A1 (en) * 2004-03-10 2005-09-15 Chih-Ping Liu Method of optimizing treatment with interferon-tau
US20050084478A1 (en) * 2000-10-17 2005-04-21 Chih-Ping Liu Combination therapy using interferon-tau
US20040247565A1 (en) * 2000-07-19 2004-12-09 Chih-Ping Liu Method of treatment using interferon-tau
US20050226845A1 (en) * 2004-03-10 2005-10-13 Chih-Ping Liu Method of treatment using interferon-tau
EP2327724A3 (en) 2004-02-02 2011-07-27 Ambrx, Inc. Modified human growth hormone polypeptides and their uses
AU2008201682B2 (en) * 2004-02-02 2011-02-24 Ambrx, Inc. Modified human interferon polypeptides and their uses
US20080025948A1 (en) * 2004-03-10 2008-01-31 Chih-Ping Liu Methods of Treatment Using Interferon-Tau
US20060078942A1 (en) * 2004-03-10 2006-04-13 Pepgen Corporation Method of treatment using interferon-tau
US7695710B2 (en) * 2005-06-20 2010-04-13 Pepgen Corporation Antitumor and antiviral combination therapies using low-toxicity, long-circulating human interferon-alpha analogs
KR20080037656A (ko) * 2005-06-20 2008-04-30 펩젠 코포레이션 저독성의 장시간 순환하는 사람 인터페론-알파 유사체 및인터페론 타우의 키메라
US20070243163A1 (en) * 2006-02-17 2007-10-18 Chih-Ping Liu Respiratory tract delivery of interferon-tau
HRP20160855T1 (hr) 2008-02-08 2016-09-23 Medimmune, Llc Anti-ifnar1 protutijela sa smanjenim afinitetom fc liganda
US11292823B2 (en) 2017-05-01 2022-04-05 Rutgers, The State University Of New Jersey Type I and type III interferon fusion molecules and methods for use thereof

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2016015B (en) * 1978-01-22 1982-05-06 Hayashibara Co Method of preparing interferon and preparations containing interferon
US4460574A (en) * 1980-06-16 1984-07-17 Yabrov Alexander A Prophylaxis or treatment of interferon-sensitive diseases
US4414150A (en) * 1980-11-10 1983-11-08 Genentech, Inc. Hybrid human leukocyte interferons
US4507281A (en) * 1981-10-13 1985-03-26 Exovir, Inc. Interferon-containing compositions
WO1983002461A1 (en) * 1982-01-19 1983-07-21 Cetus Corp Multiclass hybrid interferons
US4456784A (en) * 1982-03-26 1984-06-26 Eaton Corporation Conduit sealing connector
US6936694B1 (en) * 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
US4892743A (en) 1983-12-21 1990-01-09 Schering Corporation Novel hybrid interferon species
EP0146903A3 (en) 1983-12-19 1987-07-22 Schering Corporation Production of a vector encoding a novel hybrid interferon species
US4636383A (en) * 1984-08-29 1987-01-13 Schering Corporation Interferon-cyclaradine combination
US4724232A (en) * 1985-03-16 1988-02-09 Burroughs Wellcome Co. Treatment of human viral infections
US4895743A (en) * 1985-04-30 1990-01-23 Phillips Petroleum Company Blow molded article
DE3607835A1 (de) * 1986-03-10 1987-09-24 Boehringer Ingelheim Int Hybridinterferone, deren verwendung als arzneimittel und als zwischenprodukte zur herstellung von antikoerpern und deren verwendung sowie verfahren zu ihrer herstellung
US4846782A (en) * 1986-03-14 1989-07-11 Schering Corporation Treatment of cancer with interferon and radiotherapy
ZA878295B (en) * 1986-11-06 1988-05-03 Amarillo Cell Culture Co. Inc. Treatment of immuno-resistant disease
EP0367063A1 (en) 1988-10-26 1990-05-09 The Curators Of The University Of Missouri Isolation and cloning of complementary DNA for gene coding of bovine trophoblast protein-1
US4997646A (en) * 1989-02-23 1991-03-05 University Of Florida Research Foundation, Inc. Use of interferons of the alpha family to enhance fertility in mammals
AU5183490A (en) 1989-03-02 1990-09-26 University Of Florida Composition for the inhibition of tumors and for the non-cytotoxic inhibition of replication of viruses
US5705363A (en) * 1989-03-02 1998-01-06 The Women's Research Institute Recombinant production of human interferon τ polypeptides and nucleic acids
US5540923A (en) 1991-12-06 1996-07-30 Landsforeningen Til Kraeftens Bekaemplse Interferon proteins
AU5369794A (en) 1992-10-23 1994-05-24 Unichema Chemie Bv Condensates of metal compound and polyhydroxy compound and vinyl halide polymers stabilised therewith
CN1090510A (zh) 1992-10-30 1994-08-10 佛罗里达大学 干扰素-τ组成物及其用途
US5939286A (en) * 1995-05-10 1999-08-17 University Of Florida Hybrid interferon tau/alpha polypeptides, their recombinant production, and methods using them
EP0904373A1 (en) * 1996-03-14 1999-03-31 The Immune Response Corporation Targeted delivery of genes encoding interferon
US6204022B1 (en) 1996-04-12 2001-03-20 Pepgen Corporation And University Of Florida Low-toxicity human interferon-alpha analogs

Also Published As

Publication number Publication date
KR20040022244A (ko) 2004-03-11
EP1425409A4 (en) 2005-11-09
WO2003016472A9 (en) 2004-02-26
EP1425409A2 (en) 2004-06-09
WO2003016472A3 (en) 2003-10-16
US20030130486A1 (en) 2003-07-10
JP2005525784A (ja) 2005-09-02
CA2454860A1 (en) 2003-02-27
US7232563B2 (en) 2007-06-19
WO2003016472A2 (en) 2003-02-27

Similar Documents

Publication Publication Date Title
CN1240717C (zh) 低毒性的人干扰素－α类似物
CN1568369A (zh) 杂合的干扰素/干扰素Tau蛋白、组合物和使用方法
CN1238367C (zh) 分离的编码t细胞诱导因子(tif)的核酸分子,其编码蛋白及其应用
CN1219796C (zh) 干扰素－τ多肽的N－末端氨基酸序列的应用
CN1361793A (zh) 干扰素－α蛋白作为Fc融合蛋白的表达和运输
CN101044154A (zh) 治疗宿主中切割的嵌合分子
CN1789411A (zh) 分离的编码t细胞诱导因子(tif)的核酸分子,其编码蛋白及其应用
CN1241638C (zh) Ifnar2/ifn复合物
CN1269840C (zh) 长效的人干扰素类似物
CN1257186C (zh) 干扰素γ多肽变体
CN101045156A (zh) 特异靶向性药物及其用途
CN1718243A (zh) 一类免疫佐剂及其在抗病毒疫苗或药物制备中的应用
CN1256347C (zh) 激肽原第五结构域－肿瘤坏死因子相关凋亡诱导配体的融合蛋白及其制法和用途
CN1684979A (zh) 糖基化的人干扰素α同种型
CN1100957A (zh) 重组产品
CN1765932A (zh) 一种胸腺素α1和干扰素的融合蛋白
CN1944463A (zh) 具有α干扰素活性的融合蛋白及其编码基因与应用
CN1621411A (zh) 一种用于治疗获得性免疫缺陷综合征的重组靶向融合蛋白
CN1149291C (zh) 利用来自酿酒酵母的表达载体制备重组蛋白质的方法
CN1740197A (zh) 具有全新空间构象且功效增强的重组干扰素、其制备方法及应用
CN1896104A (zh) 细胞抑制因子与白蛋白的融合蛋白
CN88102023A (zh) 猪生长激素类似物
CN1198842C (zh) 具有细胞趋化作用和造血刺激活性的趋化素样因子
CN1300315C (zh) 奶牛之犊牛前胸腺素基因及其克隆方法与应用
CN1566155A (zh) 抗sars病毒的单克隆抗体、其编码序列及应用

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication